Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
As of May 31, 2021, the company reported a total of 55,011,687 shares outstanding. The total gross voting rights are also at 55,011,687, while the net voting rights stand at 54,943,413. This announcement complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that CEO Daniel Tassé will participate in two upcoming virtual investor conferences in June 2021. The first is at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 8:50am ET, followed by the JMP Life Sciences Conference on June 16, 2021, at 10:00am ET. A live webcast of these events will be available on the company's website, where replays will also be accessible later. DBV is focused on developing Viaskin™, a technology aimed at immunotherapy for food allergies.
DBV Technologies, a clinical-stage biopharmaceutical company, held its Ordinary and Extraordinary General Meeting on May 19, 2021, where shareholders approved all proposed resolutions. Notably, Dr. Adora Ndu and Dr. Ravi Madduri Rao were appointed as independent board members, while Dr. Torbjorn Bjerke retired. The board now consists of ten directors. Dr. Ndu and Dr. Rao bring extensive experience in drug development and regulatory affairs, aiming to support the strategic objectives of DBV, particularly in the advancement of Viaskin Peanut.
As of April 30, 2021, the company reported a total of 54,936,687 shares outstanding. The total number of voting rights amounted to 54,936,687 gross and 54,887,687 net after excluding non-voting shares. This information is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The data reflects important metrics regarding shareholder influence and governance.
DBV Technologies has filed its first Form 10-Q for Q1 2021 with the U.S. SEC. This document is available on both the company's website and the SEC’s website. DBV Technologies is focused on developing Viaskin™, a non-invasive immunotherapy platform aimed at treating food allergies, including ongoing trials for Viaskin Peanut. The company operates globally with headquarters in France and North American operations in New Jersey, and its stock is traded on Euronext Paris and Nasdaq (ticker: DBVT).
DBV Technologies reported its Q1 2021 financial results, showing a cash balance of $152.5 million as of March 31, down from $196.4 million at year-end 2020. The net loss narrowed to $(29.4 million), or $(0.54) per share, compared to $(40.9 million) and $(0.79) per share in Q1 2020. Operating income fell 37.7% to $2.9 million, primarily due to reduced research tax credits. Operating expenses decreased 29.2% to $32.6 million, attributed to workforce reductions. DBV expects current cash reserves to fund operations until mid-2022.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical firm, announced participation in two virtual investor conferences in May 2021. Dr. Pharis Mohideen and CFO Sebastien Robitaille will represent the company at the Kempen Life Sciences Conference on May 5, while CEO Daniel Tassé and Robitaille will attend the Societe Generale Nice Conference on May 27. DBV is focused on developing Viaskin™, a novel technology platform for immunotherapy aimed at treating food allergies through epicutaneous delivery.
DBVT released monthly data regarding the total number of shares and voting rights as of April 14, 2021. The total number of shares stands at 54,936,687, while the total gross of voting rights is also 54,936,687. The total net of voting rights, defined as the total voting rights minus shares without voting rights, is 54,895,437. This disclosure fulfills the requirements under Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, emphasizing transparency in shareholder voting power.
DBV Technologies announced its Ordinary and Extraordinary General Meeting is set for May 19, 2021, at 2:00 p.m. CEST, in a closed virtual session due to the COVID-19 pandemic. Shareholders are encouraged to vote remotely via postal voting, proxy, or the Votaccess platform. No physical attendance is permitted. Written questions can be submitted until May 17, 2021. The meeting will be webcasted live on the company’s website. Preparatory documents for the meeting are available for shareholders, adhering to applicable regulations.
DBV Technologies announces the provisional appointment of Timothy E. Morris as a new Board of Directors member, effective March 30, 2021. Morris, with over 20 years in biopharma, will also join the Audit Committee. His leadership experience includes roles at Humanigen, Iovance, and others, focusing on finance and commercial operations. His appointment will be ratified in a shareholder vote scheduled for May 19, 2021. DBV Technologies is known for developing Viaskin™, a platform for immunotherapy aimed at treating food allergies.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
